A recent study suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt traditional diet and exercise plans.
Findings released in a major health publication demonstrates that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these medications need to be aware of the risk of rapid weight regain when the medication ends," warns lead investigator Dr. Susan Jebb.
This pace of recovery means a return to starting mass in about one and a half years.
Weighing Approaches
The study, which reviewed dozens of studies involving thousands of participants, contrasted the results of these new drugs with conventional dieting.
Researchers point out that people who lose weight through dieting generally have a less rapid creep back—approximately 100 grams monthly—once they finish.
The Reason for the Fast Regain
Experts propose the way of the injections accounts for the amplified regain.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal may cause the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making overeating a significant risk."
A Lifelong Condition?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, given the significant potential of weight regain, the therapy is often long-term.
This view is echoed by pharmaceutical companies, who say that the results "emphasize the long-term character of obesity," comparing it to managing diseases like diabetes.
User Testimonies
Individuals who have stopped the medication report a powerful resurgence of appetite.
"It was like something flipping and you become extremely hungry," recalled one woman.
This challenge is worsened if users have not developed lasting dietary or behavioural modifications during treatment.
Widespread Use
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while these medications are powerful tools for weight loss, they are not a permanent cure and lasting health benefits likely depends on combined behavioural changes.
